The effects of morphine on carrageenin-induced spinal c-Fos expression are completely blocked by β-funaltrexamine, a selective μ-opioid receptor antagonist

Brain Research

Volumn 732, Issue 1-2, 1996, Pages 242-246

  Honoré, Prisca ^a   Buritova, Jaroslava ^a   Besson, Jean Marie ^a  

^a PSL RESEARCH UNIVERSITY   (France)

Author keywords

antinociception; c Fos; carrageenin; morphine; spinal cord; funaltrexamine; opioid receptor

Indexed keywords

BETA FUNALTREXAMINE; CARRAGEENAN; MORPHINE; MU OPIATE RECEPTOR; MU OPIATE RECEPTOR ANTAGONIST; OPIATE ANTAGONIST;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; IMMUNOCYTOCHEMISTRY; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; ONCOGENE C FOS; PRIORITY JOURNAL; RAT; SPINAL CORD;

EID: 0030565551     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/0006-8993(96)00749-4     Document Type: Article

References (33)

1. Abbadie C., Besson J.-M. Effects of morphine and naloxone on basal and evoked Fos-like immunoreactivity in lumbar spinal cord neurons of arthritic rats. Pain. 52:1993;29-39.
2. Abbadie C., Besson J.M. c-Fos expression in rat lumbar spinal cord during the development of adjuvant-Induced arthritis. Neuroscience. 48:1992;985-993.
3. Abbadie C., Honoré P., Besson J.-M. Intense cold noxious stimulation of the rat hindpaw induces c-fos expression in lumbar spinal cord neurons. Neuroscience. 59:1994;457-468.
4. Abbadie C., Honoré P., Fournié-Zaluski M.C., Roques B.P., Besson J.-M. Effects of opioids and non-opioids on c-Fos immuno-reactivity induced in rat lumbar spinal cord neurons by noxious heat stimulation. Eur. J. Pharmacol. 258:1994;215-227.
5. Adams J.U., Paronis C.A., Holtzman S.G. Assessment of relative intrinsic activity of mu-opioid analgesics in vivo by using β-funaltrexamine. J. Pharmacol. Exp. Ther. 255:1990;1027-1032.
6. Basbaum, A.I. and Besson J.M., Towards a New Therapy of Pain, Dahlem Workshop Reports, J. Wiley, New York, 1991, pp. 1-457.
7. Draisci G., Iadarola M.J. Temporal analysis of increases in c-fos, preprodynorphin and preproenkephalin mRNAs in rat spinal cord. Mol. Brain Res. 6:1989;31-37.
8. Gmerek D.A., Woods J.H. Effects of β-funaltrexamine in normal and morphine-dependent Rhesus monkeys: observational studies. J. Pharmacol. Exp. Ther. 235:1985;296-301.
9. Gogas K.R., Presley R.W., Levine J.D., Basbaum A.I. The antinociceptive action of supraspinal opioids results from an increase in descending inhibitory control: correlation of nociceptive behavior and c-fos expression. Neuroscience. 42(3):1991;617-628.
10. Hammond D.L., Presley R.W., Gogas K.R., Basbaum A.I. Morphine or U-50,488 suppresses Fos protein-like immunoreactivity in the spinal cord and nucleus tractus solitari evoked by a noxious visceral stimulus in the rat. J. Comp. Neurol. 315:1992;244-253.
11. Hayes A.G., Skingle M., Tyers M.B. Reversal by β-funaltrexamine of the antinociceptive effect of opioid agonists in the rat. Br. J. Pharmacol. 88:1986;867-872.
12. Honoré P., Buritova J., Besson J.M. Carrageenin-evoked c-Fos expression in rat lumbar spinal cord: the effects of indomethacin. Eur. J. Pharmacol. 272:1995;249-259.
13. Honoré P., Chapman V., Buritova J., Besson J.M. When is the maximal effect of pre-administered systemic morphine on carrageenin evoked spinal c-Fos expression in the rat? Brain Res. 705:1995;91-96.
14. Jasmin L., Wang H., Tarcy-Hornoch K., Levine J.D., Basbaum A.I. Differential effects of morphine on noxious stimulus-evoked Fos-like immunoreactivity in subpopulation of spinoparabrachial neurons. J. Neurosci. 14:1994;7252-7260.
15. Jiang Q., Heyman J.S., Sheldon R.J., Koslo R.J., Porreca F. Mu antagonist and kappa agonist properties of β-funaltrexamine (β-FNA) in vivo: long-lasting spinal analgesia in mice. J. Pharmacol. Exp. Ther. 252:1990;1006-1011.
16. Liu-Chen L., Yang H., Li S., Adams J.U. Effect of intracerebroventricular β-funaltrexamine on mu opioid receptors in rat brain: consideration of binding condition. J. Pharmacol. Exp. Ther. 273:1995;1047-1056.
17. Morgan, J.I., Discussions in Neuroscience, Proto-Oncogene Expression in The Nervous System, Elsevier, Amsterdam, 1991.
18. Morgan J.I., Curran T. Immediate-early genes: ten years on. Trends Neurosci. 18:1995;66-67.
19. Nozaki K., Moskowitz A., Boccalini P. CP-93,129, sumatriptan, dihydroergotamine block c-fos expression within rat trigeminal nucleus caudalis caused by chemical stimulation of the meninges. Br. J. Pharmacol. 106:1992;409-415.
20. Pitts R.C., Dykstra L.A. Antinociceptive and response rate-altering effects of kappa opioid agonists, spiradoline, enadoline and U69,593, alone and in combination with opioid antagonist in Squirrel monkeys. J. Pharmacol. Exp. Ther. 271:1994;1501-1508.
21. Portoghese P.S., Larson D.L., Sayre L.M., Fries D.S. A novel opioid receptor site directed alkylating agent with irreversible narcotic antagonistic and reversible agonistic activities. J. Med. Chem. 23:1980;233-234.
22. Presley R.W., Menétrey D., Levine J.D., Basbaum A.I. Systemic morphine suppresses noxious stimulus-evoked Fos protein-like immunoreactivity in the rat spinal cord. J. Neurosci. 10:1990;323-335.
23. Randich A., Robertson J.D., Willingham T. The use of specific opioid agonists and antagonists to delineate the vagally mediated antinociceptive and cardiovascular effects of intravenous morphine. Brain Res. 603:1993;186-200.
24. Takemori A.E., Larson D.L., Portoghese P.S. The irreversible narcotic antagonistic and reversible agonistic properties of the fumarate methyl ester derivative of naltrexone. Eur. J. Pharmacol. 70:1981;445-451.
25. Takemori A.E., Ikeda M., Portoghese P.S. The mu, kappa and delta properties of various opioid agonists. Eur. J. Pharmacol. 123:1986;357-361.
26. Takemori A.E., Portoghese P.S. Evidence for the interaction of morphine with kappa and delta opioid receptors to induce analgesia in β-funaltrexamine-treated mice. J. Pharmacol. Exp. Ther. 243:1987;91-94.
27. Tölle T.R., Schadrack J., Castro-Lopes J.M., Evan G., Roques B.P., Zieglgansberger W. Effects of kelatorphan and morphine before and after noxious stimulation on immediate-early gene expression in rat spinal cord neurons. Pain. 56:1994;103-112.
28. Tölle T.R., Castro-Lopes J.M., Coimbra A., Zieglgänsberger W. Opiates modify induction of c-fos proto-oncogene in the spinal cord of the rat following noxious stimulation. Neurosci. Lett. 111:1990;46-51.
29. Ward S.J., Portoghese P.S., Takemori A.E. Pharmacological profiles of β-funaltrexamine (β-FNA) and β-chlornaltrexamine (β-CNA) on the mouse vas deferens preparation. Eur. J. Pharmacol. 80:1982;377-384.
30. Ward S.J., Portoghese P.S., Takemori A.E. Pharmacological characterization in vivo of the novek opiate, β-Funaltrexamine. J. Pharmacol. Exp. Ther. 220:1982;494-498.
31. Zieglgänsberger W., Tölle T.R. The pharmacology of pain signalling. Curr. Opin. Neurobiol. 3:1993;611-618.
32. Zimmerman D.M., Leander J.D., Reel J.K., Hynes M.D. Use of β-funaltrexamine to determine mu opioid receptor involvement in the analgesic activity of various opioid ligands. J. Pharmacol. Exp. Ther. 241:1987;374-378.
33. Zimmermann M. Ethical guidelines for investigations of experimental pain in conscious animals. Pain. 16:1983;109-110.